Skip to main content

Table 3 Aβ + status and conversion rate at Visit 1 and Visit 2 per cluster

From: Data-driven CSF biomarker profiling: imaging and clinical outcomes in a cohort at risk of Alzheimer’s disease

Aβ PET statusa

C1 (n = 59)

C2 (n = 28)

C3 (n = 52)

Aβ-negative at Visit 1% (n)

74.6 (44)

92.9 (26)

94.2 (49)

Aβ-positive at Visit 1% (n)

25.4 (15)

7.1 (2)

5.8 (3)

Aβ-negative at Visit 2% (n)

55.9 (33)

89.3 (25)

86.5 (45)

Aβ-positive at Visit 2% (n)

44.1 (26)

10.7 (3)

13.5 (7)

Conversion to Aβ-positive at Visit 2% (n)b

25 (11)

3.8 (1)

8.2 (4)

  1. a PET data at Visit 1 and Visit 2 is available for a total of 59 participants (56.7%) in C1, 28 participants (50,9%) in C2, and 52 participants (46.8%) in C3
  2. bConversion rates to Aβ positivity status were reported based on the total number of Aβ negative participants at Visit 1
  3.  Amyloid-beta, AD Alzheimer’s disease, PET Positron emission tomography